Article info

Download PDFPDF

Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials

Authors

  1. a (732) 235-7563 howard.kaufman{at}rutgers.edu
  2. b Robert.Andtbacka{at}hci.utah.edu
  3. c frances_collichio{at}med.unc.edu
  4. d wolfm{at}amgen.com
  5. e zhongyun{at}amgen.com
  6. f mark.shilkrut{at}gmail.com
  7. g Igor.Puzanov{at}RoswellPark.org
  8. h mross{at}mdanderson.org
View Full Text

Citation

Kaufman HL, Andtbacka RHI, Collichio FA, et al
Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials

Publication history

  • Received May 4, 2017
  • Accepted August 14, 2017
  • First published September 19, 2017.
Online issue publication 
September 19, 2017

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.